文献速递泌尿男性生殖肿瘤

接受多西他赛治疗的转移性去势抵抗性前列腺癌黑人与白人男性的总生存比较

Overall Survival of Black and White Men With Metastatic Castration-Resistant Prostate Cancer Treated With Docetaxel.
PubMed 文献 · J Clin Oncol · 2018-12-21

该分析汇总9项III期试验中8,820例接受多西他赛+泼尼松(DP)或含DP方案治疗的转移性去势抵抗性前列腺癌(mCRPC)男性的个体数据,按种族(黑人 vs 白人)比较总生存(OS)。黑人男性中位OS为21.0个月(95%CI 19.4-22.5),白人男性为21.2个月(95%CI 20.8-21.7);校正已知预后因素后,黑人男性死亡风险显著低于白人男性(合并多变量HR 0.81,95%CI 0.72-0.91,P<.001)。

要点

  • 9项III期试验8,820例mCRPC男性中,黑人500例(6%),白人7,528例(85%)。
  • 黑人男性中位OS 21.0个月(95%CI 19.4-22.5)vs 白人男性21.2个月(95%CI 20.8-21.7)。
  • 校正预后因素后,黑人男性死亡风险显著低于白人男性(HR 0.81,95%CI 0.72-0.91,P<.001)。

核心结论

  • 校正已知预后因素后,这些临床试验中入组的mCRPC黑人男性较白人男性观察到统计学显著延长的OS,机制未知。

研究设计与样本

  • 汇总9项III期临床试验中8,820例随机分配至DP或含DP方案的mCRPC男性的个体参与者数据。
  • 种族基于自我报告,主要终点为OS,采用Cox比例风险回归模型评估校正年龄、前列腺特异性抗原、体能状态、碱性磷酸酶、血红蛋白和转移部位后种族的预后意义。

主要发现

  • 8,820例中白人7,528例(85%)、黑人500例(6%)、亚洲人424例(5%)、种族未知368例(4%)。
  • 黑人男性较白人男性更年轻、体能状态更差、睾酮和前列腺特异性抗原更高、血红蛋白更低。
  • 黑人男性中位OS为21.0个月(95%CI 19.4-22.5),白人男性为21.2个月(95%CI 20.8-21.7)。
  • 合并多变量HR为0.81(95%CI 0.72-0.91),黑人男性较白人男性死亡风险统计学显著降低(P<.001)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Several studies have reported that among patients with localized prostate cancer, black men have a shorter overall survival (OS) time than white men, but few data exist for men with advanced prostate cancer. The primary goal of this analysis was to compare the OS in black and white men with metastatic castration-resistant prostate cancer (mCRPC) who were treated in phase III clinical trials with docetaxel plus prednisone (DP) or a DP-containing regimen. METHODS: Individual participant data from 8,820 men with mCRPC randomly assigned in nine phase III trials to DP or a DP-containing regimen were combined. Race was based on self-report. The primary end point was OS. The Cox proportional hazards regression model was used to assess the prognostic importance of race (black v white) adjusted for established risk factors common across the trials (age, prostate-specific antigen, performance status, alkaline phosphatase, hemoglobin, and sites of metastases). RESULTS: Of 8,820 men, 7,528 (85%) were white, 500 (6%) were black, 424 (5%) were Asian, and 368 (4%) were of unknown race. Black men were younger and had worse performance status, higher testosterone and prostate-specific antigen, and lower hemoglobin than white men. Despite these differences, the median OS was 21.0 months (95% CI, 19.4 to 22.5 months) versus 21.2 months (95% CI, 20.8 to 21.7 months) in black and white men, respectively. The pooled multivariable hazard ratio of 0.81 (95% CI, 0.72 to 0.91) demonstrates that overall, black men have a statistically significant decreased risk of death compared with white men ( P < .001). CONCLUSION: When adjusted for known prognostic factors, we observed a statistically significant increased OS in black versus white men with mCRPC who were enrolled in these clinical trials. The mechanism for these differences is not known.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Halabi S, Dutta S, Tangen CM, et al. Overall Survival of Black and White Men With Metastatic Castration-Resistant Prostate Cancer Treated With Docetaxel. J Clin Oncol. 2018. PMID: 30576268. doi:10.1200/JCO.18.01279

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。